BC Extra | Sep 30, 2019
Company News

Sobi adding to U.S. presence, hematology pipeline via $915M Dova takeout

With the $915 million takeout of Dova Pharmaceuticals and a co-development deal with Sanofi in hemophilia, Sobi is continuing its push into the U.S. and strengthening its presence in hematology. Swedish Orphan Biovitrum AB (SSE:SOBI)...
BC Extra | Aug 23, 2019
Company News

Aug. 22 Company Quick Takes: Innovent, Lilly in biologics deal; plus Sobi, Gilead, Themis-Merck, Iconic-Novartis, GW, BeiGene, Clearside, Inex Innovations

Innovent, Lilly in third biologics deal  Innovent Biologics Inc. (HKEX:1801) in-licensed Chinese rights to OXM3 from Eli Lilly and Co. (NYSE:LLY) to treat diabetes. The oxyntomodulin analog -- a dual agonist of GLP-1R and GCGR...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
BC Extra | Jul 23, 2019
Company News

Management tracks: Epizyme, Disarm, Kaleido, Selecta and more

Epigenetics company Epizyme Inc . (NASDAQ:EPZM) hired Paolo Tombesi as CFO, effective next month. He was CFO at Insmed Inc. (NASDAQ:INSM). Disarm Therapeutics Inc. (Cambridge, Mass.), which is focused on therapies for axonal degeneration, hired Alvin...
BC Extra | Jun 13, 2019
Company News

Sobi buying Novimmune assets as it refocuses R&D

Less than a year after gaining an exclusive worldwide license for Gamifant emapalumab from Novimmune, Sobi is acquiring a newco formed around the hematology therapy for CHF515 million ($519.2 million) and restructuring its R&D pipeline...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BC Innovations | Mar 4, 2019
Distillery Therapeutics

New bacteriophage-related therapeutic strategies for colitis and colorectal cancer

DISEASE CATEGORY: Cancer; gastrointestinal INDICATION: Colorectal cancer; colitis Patient sample and mouse studies suggest an E. coli bacteriophage cocktail could help treat bacteria-aggravated colorectal cancer and blockade of host-bacteriophage interactions via inhibition of IFNγ or...
BioCentury | Jan 12, 2019
Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Extra | Jan 3, 2019
Company News

Management tracks: Barrett joins UroGen

Uro-oncology company UroGen Pharma Ltd. (NASDAQ:URGN) named Elizabeth Barrett as president and CEO. She replaces Ron Bentsur. Last month, Barrett joined the exodus of pharma leaders heading to biotech as she departed Novartis AG (NYSE:NVS;...
Items per page:
1 - 10 of 114
BC Extra | Sep 30, 2019
Company News

Sobi adding to U.S. presence, hematology pipeline via $915M Dova takeout

With the $915 million takeout of Dova Pharmaceuticals and a co-development deal with Sanofi in hemophilia, Sobi is continuing its push into the U.S. and strengthening its presence in hematology. Swedish Orphan Biovitrum AB (SSE:SOBI)...
BC Extra | Aug 23, 2019
Company News

Aug. 22 Company Quick Takes: Innovent, Lilly in biologics deal; plus Sobi, Gilead, Themis-Merck, Iconic-Novartis, GW, BeiGene, Clearside, Inex Innovations

Innovent, Lilly in third biologics deal  Innovent Biologics Inc. (HKEX:1801) in-licensed Chinese rights to OXM3 from Eli Lilly and Co. (NYSE:LLY) to treat diabetes. The oxyntomodulin analog -- a dual agonist of GLP-1R and GCGR...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
BC Extra | Jul 23, 2019
Company News

Management tracks: Epizyme, Disarm, Kaleido, Selecta and more

Epigenetics company Epizyme Inc . (NASDAQ:EPZM) hired Paolo Tombesi as CFO, effective next month. He was CFO at Insmed Inc. (NASDAQ:INSM). Disarm Therapeutics Inc. (Cambridge, Mass.), which is focused on therapies for axonal degeneration, hired Alvin...
BC Extra | Jun 13, 2019
Company News

Sobi buying Novimmune assets as it refocuses R&D

Less than a year after gaining an exclusive worldwide license for Gamifant emapalumab from Novimmune, Sobi is acquiring a newco formed around the hematology therapy for CHF515 million ($519.2 million) and restructuring its R&D pipeline...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BC Innovations | Mar 4, 2019
Distillery Therapeutics

New bacteriophage-related therapeutic strategies for colitis and colorectal cancer

DISEASE CATEGORY: Cancer; gastrointestinal INDICATION: Colorectal cancer; colitis Patient sample and mouse studies suggest an E. coli bacteriophage cocktail could help treat bacteria-aggravated colorectal cancer and blockade of host-bacteriophage interactions via inhibition of IFNγ or...
BioCentury | Jan 12, 2019
Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Extra | Jan 3, 2019
Company News

Management tracks: Barrett joins UroGen

Uro-oncology company UroGen Pharma Ltd. (NASDAQ:URGN) named Elizabeth Barrett as president and CEO. She replaces Ron Bentsur. Last month, Barrett joined the exodus of pharma leaders heading to biotech as she departed Novartis AG (NYSE:NVS;...
Items per page:
1 - 10 of 114